About Contact Us Careers
Sign In

Non-Cancerous Blood Disease Market - Top Companies and Manufacturers

  • Report ID: 4037
  • Published Date: Aug 19, 2024
  • Report Format: PDF, PPT
  1. Market Definition and Research Methodology
    1. Market Definition and Segmentation
    2. Assumptions and Acronyms
    3. Research Objective
    4. Research Methodology
  2. Executive Summary
  3. Market Dynamics
    1. Growth Drivers
    2. Market Trends
  4. Key Market Opportunities
  5. Major Roadblocks for the Market Growth
  6. Regulatory & Standards Landscape
  7. Industry Risk Analysis
  8. Analysis on Treatment Type
  9. Epidemiology Analysis
  10. R&D Pipeline Analysis
  11. Proportion of Healthcare Expenditure (%) by Category and Blood Disorder Type, 2021
  12. Analysis on the Existing Drug in the Market
  13. Competitive Positioning
  14. Competitive Structure
    1. SANOFI
    2. Novo Nordisk A/S
    3. Novartis AG
    4. Pfizer Inc.
    5. Amgen Inc.
    6. Alexion Pharmaceuticals, Inc.
    7. Bayer AG
    8. Bristol Myers Squibb Company
    9. F. Hoffmann-La Roche Ltd.
    10. Takeda Pharmaceutical Company Limited
    11. CSL Behring
  15. Global Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
        1. Anemia, 2021-2031F (USD Million)
          1. Aplastic Anemia, 2021-2031F (USD Million)
          2. Hemolytic Anemia, 2021-2031F (USD Million)
          3. Iron Deficiency Anemia, 2021-2031F (USD Million)
          4. Sickle Cell Anemia, 2021-2031F (USD Million)
          5. Others, 2021-2031F (USD Million)
        2. Bleeding Disorders, 2021-2031F (USD Million)
          1. Hemophilia, 2021-2031F (USD Million)
          2. Von Willebrand Disease, 2021-2031F (USD Million)
          3. Others, 2021-2031F (USD Million)
        3. Platelet Disorders, 2021-2031F (USD Million)
          1. Autoimmune Thrombocytopenia, 2021-2031F (USD Million)
          2. Thrombocytopenia, 2021-2031F (USD Million)
          3. Thrombocytosis, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        4. White Blood Cell Disorders, 2021-2031F (USD Million)
          1. Basophilic Disorders, 2021-2031F (USD Million)
          2. Lymphocytopenia, 2021-2031F (USD Million)
          3. Neutropenia, 2021-2031F (USD Million)
          4. Systemic Mastocytosis, 2021-2031F (USD Million)
          5. Others, 2021-2031F (USD Million)
        5. Plasma Cell Disorders, 2021-2031F (USD Million)
          1. Macroglobulinemia, 2021-2031F (USD Million)
          2. POEMS Syndrome, 2021-2031F (USD Million)
          3. Cryoglobulinemia, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        6. Rare Hematological Disorders, 2021-2031F (USD Million)
          1. Amyloidosis, 2021-2031F (USD Million)
          2. Castleman Disease, 2021-2031F (USD Million)
          3. Paroxysmal Nocturnal Hemoglobinuria, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        7. Spleen Disorders, 2021-2031F (USD Million)
      2. By Treatment Type
        1. Antibiotics, 2021-2031F (USD Million)
        2. Blood Transfusion, 2021-2031F (USD Million)
        3. Infusion Therapy, 2021-2031F (USD Million)
        4. Dietary Supplements or Chelators, 2021-2031F (USD Million)
        5. Others, 2021-2031F (USD Million)
      3. By Gender
        1. Male, 2021-2031F (USD Million)
        2. Female, 2021-2031F (USD Million)
      4. By End-User
        1. Hospitals, 2021-2031F (USD Million)
        2. Clinics, 2021-2031F (USD Million)
        3. Others, 2021-2031F (USD Million)
      5. By Region
        1. North America, 2021-2031F (USD Million)
        2. Europe, 2021-2031F (USD Million)
        3. Asia Pacific, 2021-2031F (USD Million)
        4. Latin America, 2021-2031F (USD Million)
        5. Middle East & Africa, 2021-2031F (USD Million)
  16. North America Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
        1. Anemia, 2021-2031F (USD Million)
          1. Aplastic Anemia, 2021-2031F (USD Million)
          2. Hemolytic Anemia, 2021-2031F (USD Million)
          3. Iron Deficiency Anemia, 2021-2031F (USD Million)
          4. Sickle Cell Anemia, 2021-2031F (USD Million)
          5. Others, 2021-2031F (USD Million)
        2. Bleeding Disorders, 2021-2031F (USD Million)
          1. Hemophilia, 2021-2031F (USD Million)
          2. Von Willebrand Disease, 2021-2031F (USD Million)
          3. Others, 2021-2031F (USD Million)
        3. Platelet Disorders, 2021-2031F (USD Million)
          1. Autoimmune Thrombocytopenia, 2021-2031F (USD Million)
          2. Thrombocytopenia, 2021-2031F (USD Million)
          3. Thrombocytosis, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        4. White Blood Cell Disorders, 2021-2031F (USD Million)
          1. Basophilic Disorders, 2021-2031F (USD Million)
          2. Lymphocytopenia, 2021-2031F (USD Million)
          3. Neutropenia, 2021-2031F (USD Million)
          4. Systemic Mastocytosis, 2021-2031F (USD Million)
          5. Others, 2021-2031F (USD Million)
        5. Plasma Cell Disorders, 2021-2031F (USD Million)
          1. Macroglobulinemia, 2021-2031F (USD Million)
          2. POEMS Syndrome, 2021-2031F (USD Million)
          3. Cryoglobulinemia, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        6. Rare Hematological Disorders, 2021-2031F (USD Million)
          1. Amyloidosis, 2021-2031F (USD Million)
          2. Castleman Disease, 2021-2031F (USD Million)
          3. Paroxysmal Nocturnal Hemoglobinuria, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        7. Spleen Disorders, 2021-2031F (USD Million)
      2. By Treatment Type
        1. Antibiotics, 2021-2031F (USD Million)
        2. Blood Transfusion, 2021-2031F (USD Million)
        3. Infusion Therapy, 2021-2031F (USD Million)
        4. Dietary Supplements or Chelators, 2021-2031F (USD Million)
        5. Others, 2021-2031F (USD Million)
      3. By Gender
        1. Male, 2021-2031F (USD Million)
        2. Female, 2021-2031F (USD Million)
      4. By End-User
        1. Hospitals, 2021-2031F (USD Million)
        2. Clinics, 2021-2031F (USD Million)
        3. Others, 2021-2031F (USD Million)
      5. By Country
        1. United States, 2021-2031F (USD Million)
        2. Canada, 2021-2031F (USD Million)
  17. Europe Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
      2. By Treatment Type
      3. By Gender
      4. By End-User
      5. By Country
        1. United Kingdom, 2021-2031F (USD Million)
        2. Germany, 2021-2031F (USD Million)
        3. Italy, 2021-2031F (USD Million)
        4. France, 2021-2031F (USD Million)
        5. Russia, 2021-2031F (USD Million)
        6. Rest of Europe, 2021-2031F (USD Million)
  18. Asia Pacific Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
      2. By Treatment Type
      3. By Gender
      4. By End-User
      5. By Country
        1. China, 2021-2031F (USD Million)
        2. Japan, 2021-2031F (USD Million)
        3. Singapore, 2021-2031F (USD Million)
        4. South Korea, 2021-2031F (USD Million)
        5. India, 2021-2031F (USD Million)
        6. Australia, 2021-2031F (USD Million)
        7. Rest of APAC, 2021-2031F (USD Million)
  19. Latin America Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
      2. By Treatment Type
      3. By Gender
      4. By End-User
      5. By Country
        1. Brazil, 2021-2031F (USD Million)
        2. Argentina, 2021-2031F (USD Million)
        3. Mexico, 2021-2031F (USD Million)
        4. Rest of LATAM, 2021-2031F (USD Million)
  20. Middle East & Africa Non-Cancerous Blood Disease Market
    1. By Value (USD Million)
    2. Market Segmentation Analysis 2021-2031
      1. By Disorder Type
      2. By Treatment Type
      3. By Gender
      4. By End-User
      5. By Country
        1. GCC, 2021-2031F (USD Million)
        2. Israel, 2021-2031F (USD Million)
        3. South Africa, 2021-2031F (USD Million)
        4. Rest of MEA, 2021-2031F (USD Million)
  21. Primary Interview Analysis
  22. Secondary Research Analysis
  23. Methodology: Global Non-Cancerous Blood Disease Market

Companies Dominating the Non-Cancerous Blood Disease Landscape

    Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global non-cancerous blood disease market that are included in our report are

    • SANOFI,
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Novo Nordisk A/S,
    • Novartis AG, Pfizer Inc.,
    • Amgen Inc.,
    • Alexion Pharmaceuticals, Inc.,
    • Bayer AG,
    • Bristol Myers Squibb Company,
    • F. Hoffmann-La Roche Ltd.,
    • Takeda Pharmaceutical Company Limited,
    • CSL Behring

     

Browse Key Market Insights with Data Illustration:

In the News

  • February 4th, 2022: SANOFI announced that it has received approval for Enjaymo, the first and only approved treatment for use in patients with cold agglutinin disease, by the United States Food and Drug Administration (FDA).

  • November 5th, 2020: CSL Behring announced that it has received Marketing Authorization Application (MAA) by the chief scientific body of the European Medicines Agency (EMA), the Committee for Medicinal Products for Human Use (CHMP), for its investigational gene therapy, etranacogene dezaparvovec, also known as EtranaDez, applicable for people living with the life-threatening bleeding disorder, hemophilia B.


Author Credits:  Radhika Pawar


  • Report ID: 4037
  • Published Date: Aug 19, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of non-cancerous blood disease is assessed at USD 66.71 billion.

Non-Cancerous Blood Disease Market size was over USD 63.41 billion in 2023 and is projected to exceed USD 143.78 billion by 2036, growing at over 6.5% CAGR during the forecast period i.e., between 2024-2036. The increasing prevalence of various non-cancerous blood disorders, growing number of hemoglobinopathies immigrants, and escalating need for early diagnosis of diseases will boost the market growth.

North America industry is poised to dominate 37% revenue share by 2036, attributed to growing awareness for non-cancerous blood diseases, along with rising concern for the increasing economic burden of non-malignant blood disorders.

The major players in the market are SANOFI, Novo Nordisk A/S, Novartis AG, Pfizer Inc., Amgen Inc., Alexion Pharmaceuticals, Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., and others.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample